Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Netscientific Appoints Ian Postlethwaite as CFO

5 Apr 2016 07:00

RNS Number : 1367U
NetScientific PLC
05 April 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

 

London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

 

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

 

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

 

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

 

 

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

 

Allergy Therapeutics Italia s.r.l.

 

Allergy Therapeutics Iberia S.L.

 

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

 

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALFFEISRISIIR
Date   Source Headline
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:36 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 20204:40 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:02 pmRNSPDS Initiates Programs for COVID-19, PDS0101 delay
14th Apr 20207:04 amRNSPDS Appoints Ilian Iliev to the Board
31st Mar 20207:00 amRNSBoard Changes
30th Mar 20209:39 amRNSHolding(s) in Company
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering
15th Jan 20207:00 amRNSBoard Change
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.